Acadia Healthcare Ups Guidance Amid Mixed Headwinds

Acadia Healthcare Company, Inc. ((ACHC)) has held its Q1 earnings call. Read on for the main highlights of the call.

Acadia Healthcare opened 2026 on an upbeat note, as management highlighted solid revenue and EBITDA growth, successful cost-cutting efforts and better execution across its acute and residential treatment center network. While specialty segment weakness, payer pushback and start‑up drag remain obstacles, executives argued that margin progress and operational discipline are beginning to outweigh these headwinds.

Revenue Growth and Same-Facility Improvement

Acadia reported first‑quarter revenue of $828.8 million, up 7.6% from a year ago, with same‑facility sales growing 7.3%. That gain was fueled by a 5.6% rise in revenue per patient day and a 1.6% increase in patient days, underscoring both stronger pricing and modest volume growth across the core portfolio.

Strong Acute and RTC Performance

The acute segment remained the growth engine, with revenue up 14.2% year over year, supported by higher patient volumes and ramping new facilities. Residential treatment centers also contributed, posting a 6.3% revenue increase as new programs and beds came online and existing locations became more productive.

Adjusted EBITDA Outperformance

Adjusted EBITDA reached $144.2 million in the quarter, a 7.5% increase that came in $7.2 million above the high end of guidance. Same‑facility adjusted EBITDA was $199.5 million, signaling that core operations are scaling efficiently even as the company absorbs start‑up losses and closure-related noise.

Raised Full-Year Profitability Guidance

On the back of the beat, management nudged full‑year profitability targets higher, raising the adjusted EBITDA range to $580 million–$615 million from $575 million–$610 million. Adjusted earnings per share guidance was also lifted, to $1.35–$1.60 from a prior $1.30–$1.55, reflecting growing confidence in margin expansion.

Operational Execution and Cost Efficiency

Executives emphasized that organizational restructuring and corporate headcount reductions are already paying off, with cost efficiencies running ahead of plan at both corporate and facility levels. Start‑up losses totaled $12 million in the quarter, about $2 million better than forecast, highlighting tighter control over new facility ramp‑up costs.

Bed and JV Development Progress

Growth investments continue, with 82 beds added in the first quarter and a pipeline to add 400–600 beds in 2026. The company opened a joint venture with Tufts, currently operating 24 beds with capacity to serve 144 when fully licensed, and expects additional JV facilities with partners in Orlando and Iowa to open in the second quarter.

Balance Sheet and Liquidity

As of March 31, Acadia held $158 million in cash and had roughly $565 million available under its $1 billion revolving credit facility. Net leverage stood around 3.9 times adjusted EBITDA, and management expects year‑end leverage in the 3.9–4.2 times range, balancing growth spending with balance‑sheet discipline.

Improved Workforce Metrics and Quality Focus

Staff retention improved for the eighth straight quarter, a key metric in a labor‑intensive sector where turnover can disrupt care and margins. Management also stressed a renewed focus on clinical quality, outcome metrics, stronger referral relationships and early use of technology, including AI pilots, to improve operations and revenue cycle performance.

Cash Flow Improvement vs Prior Year

Operating cash flow reached $62 million, while capital spending of $77 million yielded a modest negative free cash flow of $15 million in the quarter. Even so, that was a $148 million improvement over the prior year’s first quarter, reinforcing management’s view that free cash flow will turn positive for 2026 despite elevated investment.

Q2 Guidance and Near-Term Clarity

To frame short‑term expectations, Acadia guided second‑quarter revenue to $835 million–$850 million, with adjusted EBITDA between $142 million and $152 million and EPS of $0.30–$0.40. The company noted that timing differences in supplemental payments, particularly versus last year, are influencing quarter‑to‑quarter comparisons but not the overall full‑year outlook.

Specialty Segment Pressure and Revenue Decline

Not all segments are firing, as specialty facility revenue fell 6.5% year over year in the quarter, largely due to issues in Pennsylvania and prior‑year closures. A major factor was New York’s decision to stop sending residents to Pennsylvania facilities, and management noted that closures alone created nearly a 6% headwind to growth.

CTC Growth Slowed and Weather Impact

Comprehensive treatment center revenue increased only 2.5% year over year and decelerated sequentially, with severe winter weather forcing some sites to temporarily close. Management estimated that weather reduced adjusted EBITDA by $3.7 million in the quarter, highlighting the vulnerability of some locations to short-term external shocks.

Higher Bad Debts and Payer Denials

Acadia faced higher‑than‑expected bad debts and payer denials in the quarter, reflecting broad‑based pushback across payer types. In response, the company has baked modestly higher bad debt and denial levels into its full‑year guidance and is working to tighten documentation and appeals processes as accounts receivable days drift higher.

Temporary Near-Term Leverage Increase

Because of the timing of certain supplemental payments, including a sizable Tennessee program in the prior year, management expects net leverage to temporarily rise to roughly 4.4–4.5 times at the end of the second quarter. The company argues that as supplemental payments normalize and earnings build later in the year, leverage should migrate back to the 3.9–4.2 times target range.

Free Cash Flow Still Negative and CapEx Elevated

Despite the year‑on‑year improvement, free cash flow remained slightly negative in the first quarter as capital spending stays elevated to support JV openings and bed additions. Full‑year capital expenditure is projected at $255 million–$280 million, with a heavier skew in the first half, but management still expects positive free cash flow for 2026.

Start-Up and Closure Headwinds

The company closed 251 beds in the quarter, mainly leased facilities in Pennsylvania and other previously announced sites, which continues to weigh on reported growth. At the same time, start‑up facility losses are expected to remain significant, with guidance implying $47 million–$51 million in losses for the full year as new projects ramp toward profitability.

One-Time Benefit and Supplemental Program Uncertainty

First‑quarter results also included a $3.2 million benefit tied to employee benefit costs that management expects will reverse in the back half of 2026, muting its ongoing contribution. Executives highlighted supplemental payment programs under regulatory review that could add at least $22 million of EBITDA if approved, but they stressed that these potential benefits are excluded from current guidance due to uncertainty.

Broad-Based Payer Pushback

Management described payer behavior as a broad‑based challenge, with denials and collection pressure coming from multiple payer categories rather than a single bad actor. To counter this, Acadia is rolling out enterprise‑wide remediation and appeals initiatives while monitoring rising accounts receivable days, seeking to protect both revenue and cash conversion.

Forward-Looking Guidance and Outlook

Looking ahead, Acadia reaffirmed full‑year revenue guidance of $3.37 billion–$3.45 billion while nudging profitability targets higher on the strength of early‑year execution. Management’s outlook balances continued investment in beds and joint ventures, expected positive free cash flow and gradual de‑leveraging against acknowledged risks from payer dynamics, supplemental approval timing and ongoing start‑up losses.

Acadia’s latest earnings call painted the picture of a company tightening operational screws and expanding capacity while navigating a tougher reimbursement and regulatory landscape. Investors weighing the stock will need to balance the clear momentum in acute care and margin gains against persistent specialty softness, payer friction and the temporary uptick in leverage as supplemental payments ebb and flow.